Clinical Trial Update: Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the addition of Triapine to Lutetium-177 dotatate radioligand therapy for metastatic neuroendocrine tumors; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Digestive System Neuroendocrine Neoplasm
• Neuroendocrine Tumor

Drugs mentioned

• Lutetium-177 dotatate (Lutetium-177 dotatate)
• Triapine (Triapine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Neuroendocrine Tumor | Phase 1 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-11-03